Usted buscó: bleomycin (Inglés - Maltés)

bleomycin teva
bleomycin teva

what is bleomycin?
x’ inhu bleomycin?

why was bleomycin reviewed?
għaliex ġie rivedut bleomycin?

bleomycin teva 15 u (usp)/ vial
bleomycin teva, pulver 15 u

bleomycin teva swensweg 5 p. o.
bleomycin teva swensweg 5 p. o.

bleomycin is intended for the treatment of:
il- bleomiċina hija destinata għat- trattament ta ’:

bleomycin-teva práš ok na injekč ný roztok
bleomicina teva

bleomycin-teva 15u, práš ek pro př ípravu injekč ního roztoku
bleomycin- teva 15u,

in a lower degree bleomycin also affects the rna and protein synthesis.
fi grad iktar baxx, il- bleomiċina taffettwa wkoll l- rna u s- sinteżi tal- proteini.

- the observed toxicity risks are outweighed by the established efficacy of bleomycin,
- ir- riskji tat- tossiċità osservati huma megħlubin mill- effikaċja stabbilita tal- bleomiċina;

bleomycin teva, pulver 15 u (usp)/ vial og væske til injeksjonsvæske, oppløsning
bleomycine 15 u (usp), 15 u

bleomycin is a cytostatic substance; this means that it stops the growth of cells.
bleomycin huwa sustanza ċitostatika; dan ifisser li jwaqqaf it- tkabbir taċ- ċelloli.

bleomycin „ pharmachemie“ 15000 i. e. - pulver zur herstellung einer injektionslösung
bleomycin „ pharmachemie “ 15000

bleomycin is almost always used in combination with anti-cancer drugs or in combination with radiation.
bleomycin jintuża kważi dejjem f’ kombinazzjoni ma ’ pilloli kontra l- kanċer jew f’ kombinazzjoni mar - radjazzjoni.

overall summary of the scientific evaluation of bleomycin pharmachemie and associated names (see annex i)
sommarju Ġenerali tal- evalwazzjoni xjentifika ta ’ bleomycin pharmachemie u ismijiet assoĊjati (ara anness i)

the chmp noted that bleomycin is in clinical use since the 1960ies, thereby explaining the lack of a clinical development programme.
is- chmp innota li l- bleomiċina ilha f’ użu kliniku mis- snin sittin, b’ hekk jispjega n- nuqqas ta ’ programm ta ’ żvilupp kliniku.

7 this indication, as well as in penile cancer, several recent trials have illustrated the significance of bleomycin in these indications.
8 modesta f’ din l- indikazzjoni, kif ukoll f’ kanċer tal- pene, diversi provi reċenti wrew is- sinifikat tal - bleomiċina f’ dawn l- indikazzjonijiet.

adcetris must not be used together with bleomycin (another cancer medicine) as this combination is damaging to the lungs.
adcetris ma għandux jintuża flimkien ma bleomycin (mediċina oħra kontra l-kanċer) peress li din il- kombinazzjoni hija ta' ħsara għall-pulmuni.

an increased chromosome fragility has been observed in one in vitro study on lymphocytes taken from patients after long term treatment with somatropin and following the addition of the radiomimetic drug bleomycin.
Żieda fil-fraġilità tal-kromosomi kienet osservata fi studju in vitro fuq limfoċiti meħuda minn pazjenti wara kura fit-tul b’somatropin u wara ż-żieda tal-mediċina radjumimetika bleomycin.

regarding the indication in epidermoid carcinoma of external genitalia, the chmp noted that bleomycin is currently still in use in cervical cancer, and it was agreed that although the clinical efficacy is modest in
rigward l- indikazzjoni ta ’ karċinoma epidermojde tal- ġenitali esterni, is- chmp innota li l- bleomiċina bħalissa xorta għadha tintuża f’ kanċer taċ- ċerviċi, u sar qbil fuq il- fatt li għalkemm l- effikaċja klinika hija